Enterprise Value
17.87M
Cash
351K
Avg Qtr Burn
-496.5K
Short % of Float
4.03%
Insider Ownership
45.03%
Institutional Own.
1.12%
Qtr Updated
03/31/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Fexapotide (NX-1207) Details Inflammatory disease, Prostate disease, Benign prostatic hyperplasia (BPH) | NDA Submission | |
Fexapotide (NX-1207) Details Prostate Cancer (Early Stage) | Phase 2 Initiation |